Table 3. mAb passive protection studies in mouse models of systemic and mucosal ricin challenge.
| Intraperitoneal | Intranasal | |||||
|---|---|---|---|---|---|---|
| Group | Survivors | p-valuea | HR (95% CI)b | Survivors | p-valuea | HR (95% CI) b |
| SylH3 | 9/10 | 0.0001 | 0.0022 (0.0002–0.0190) | 8/10 | 0.0007 | 0.0280 (0.0054–0.1438) |
| 24B11 | 3/5 | 0.0275 | 0.0096 (0.0018–0.0510) | 1/5 | 0.3333 | 0.1457 (0.0415–0.5112) |
| MH3 | 7/10 | 0.0031 | 0.0098 (0.0029–0.0335) | 2/10 | 0.4737 | 0.2227 (0.0791–0.6270) |
| 8A1 | 1/5 | 0.3571 | 0.0577 (0.0157–0.2120) | - | - | - |
| 8B3 | 3/10 | 0.2105 | 0.0289 (0.0100–0.0836) | - | - | - |
| LF1 | 0/10 | >0.9999 | 0.1171 (0.0465–0.2951) | - | - | - |
| LC5 | 0/5 | >0.9999 | 0.1848 (0.0707–0.4828) | 0/5 | >0.9999 | 0.8302 (0.2803–2.4585)* |
| Control | 0/9 | - | - | 0/10 | - | - |
a, p-values of Fisher’s exact tests comparing survival between individual experimental groups and the control group.
b, in all cases the Cox regression analysis indicated that mAb treatment was significantly beneficial (p-values <0.01) except for LC5 treatment in the intranasal group (p = 0.74).